Dear Colleagues,

Hyperthermia (HT) corresponds to the increase in temperature of several degrees in human or animal organ tissue with the goal of achieving an anti-tumoral effect. To be specific, HT has multiple anti-cancer mechanisms, including the inhibition of DNA-damage repair, changes in perfusion, re-oxygenation with hypoxia reduction and anti-angiogenetic effects, the induction of heat-shock proteins, and immunological stimulation. In the last several decades, HT has been identified as the fourth pillar of anticancer treatment, alone or in combination with surgery, radiotherapy, and/or chemotherapy/immunotherapy. In this regard, the synergic anti-cancer effect between some chemotherapeutic drugs, immunotherapeutic agents, radiotherapy, and HT has been described. Moreover, many oncological clinical trials have demonstrated the significant improvement in clinical outcomes from adding HT to standard treatment regimens. The HT technique works through different types of medical devices. With special reference to external loco-regional HT, this includes: capacitive HT, radiative HT, hyperthermic intraperitoneal chemotherapy and hyperthermic isolated limb perfusion.

In this Special Issue, we would like to focus attention on clinical outcomes deriving from HT alone and in combination with standard treatment regimens in several cancers, underlining biological anti-cancer mechanisms. Unsolicited and solicited original papers and review articles will be welcome for this Special Issue.

Dr. Cosmo Damiano Gadaleta
Prof. Girolamo Ranieri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• capacitive hyperthermia
• radiative hyperthermia
• hyperthermic intraperitoneal chemotherapy
• hyperthermic isolated limb perfusion
• chemotherapy
• immunotherapy
• radiotherapy